Cranial Nerve Involvement in Systemic Sclerosis (Scleroderma): A Report of 10 Cases.
Medicine (Impact Factor: 5.72). 04/1980; 59(2):149-59. DOI: 10.1097/00005792-198003000-00006
Ten patients with the diagnosis of systemic sclerosis developed cranial nerve involvement. A trigeminal sensory neuropathy evolved insidiously in all patients and in five of these it was a presenting complaint. The glossopharyngeal nerve was involved in one patient. Taste was impaired in one patient and a unilateral loss of taste with fasciculations of the tongue were noted in another. Tinnitus was a complaint in three patients, two of whom had bilateral impairment of hearing. Facial weakness was noted in five patients. In three, this weakness was bilateral, while in the others the weakness was unilateral, and a past history of acute onset was obtained. The microangiopathy of systemic sclerosis is felt to be primarily responsible for these neurological deficits. The deposition of fibrous tissue may be a secondary phenomenon and contribute to the process by compression of nerves.
- [Show abstract] [Hide abstract]
ABSTRACT: Trigeminal neuropathy was identified in 16 (4 percent) of 442 consecutive patients with progressive systemic sclerosis (PSS) who were first evaluated during the period between 1972 and 1980. These cases, together with 25 others that are adequately documented in the literature, were reviewed and compared with the 426 cases of PSS (96 percent) without trigeminal neuropathy. Trigeminal neuropathy occurred most frequently in young women with PSS in overlap with other disorders, particularly the mixed connective tissue disease syndrome with clinical evidence of myositis. Serum antibodies to ribonucleoprotein were identified in nine (45 percent) of 20 PSS patients with trigeminal neuropathy as compared to 25 (8 percent) of 329 PSS patients without trigeminal neuropathy. Leukopenia, hypothyroidism, and Sjögren's syndrome were also found to be associated with trigeminal neuropathy.The American Journal of Medicine 08/1982; 73(1):57-62. DOI:10.1016/0002-9343(82)90926-3 · 5.00 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: There were 4 men and 8 women, aged 27 to 51 years. All had moderately severe gait disorders caused by corticospinal dysfunction, some with and some without cerebellar involvement and were classified as Mobility Scale Class III using the McAlpine classification. All patients could walk at least 10 meters, with or without assistance, but not more than one city block. They could stand alone and transfer from wheelchair to bed without assistance. Nonmotor phenomena, even though present, were not considered in the patient selection. All patients had requested HBO treatment without my prior mention of it. Treatment consisted of five one-hour sessions per week for four weeks, each session consisting of the administration of pure oxygen under two atmospheres of pressure in a hyperbaric oxygen chamber. An oxygen mask was nor used. These data indicate HBO has no objective benefit in the treatment of moderately advanced multiple sclerosis.Annals of Neurology 06/1985; 17(6):615 - 615. DOI:10.1002/ana.410170616 · 9.98 Impact Factor
- Annals of Neurology 07/1985; 17(6):615-7. DOI:10.1002/ana.410170617 · 9.98 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.